<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:32:28Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8417842" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8417842</identifier>
        <datestamp>2021-09-08</datestamp>
        <setSpec>oncologist</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="onco13883" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Oncologist</journal-id>
              <journal-id journal-id-type="iso-abbrev">Oncologist</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1549-490X</journal-id>
              <journal-id journal-id-type="publisher-id">ONCO</journal-id>
              <journal-id journal-id-type="hwp">theoncologist</journal-id>
              <journal-title-group>
                <journal-title>The Oncologist</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1083-7159</issn>
              <issn pub-type="epub">1549-490X</issn>
              <publisher>
                <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
                <publisher-loc>Hoboken, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8417842</article-id>
              <article-id pub-id-type="pmcid">PMC8417842</article-id>
              <article-id pub-id-type="pmc-uid">8417842</article-id>
              <article-id pub-id-type="pmid">34190370</article-id>
              <article-id pub-id-type="pmid">34190370</article-id>
              <article-id pub-id-type="doi">10.1002/onco.13883</article-id>
              <article-id pub-id-type="publisher-id">ONCO13883</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>10</subject>
                </subj-group>
                <subj-group subj-group-type="overline">
                  <subject>Gynecologic Oncology</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Gynecologic Oncology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab</article-title>
                <alt-title alt-title-type="right-running-head">Adverse Reactions with Lenvatinib + Pembrolizumab</alt-title>
                <alt-title alt-title-type="left-running-head">Makker, Taylor, Oaknin et al.</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="onco13883-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Makker</surname>
                    <given-names>Vicky</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9793-7614</contrib-id>
                  <xref rid="onco13883-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <address>
                    <email>makkerv@mskcc.org</email>
                  </address>
                </contrib>
                <contrib id="onco13883-cr-0002" contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Matthew H.</given-names>
                  </name>
                  <xref rid="onco13883-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="onco13883-cr-0003" contrib-type="author">
                  <name>
                    <surname>Oaknin</surname>
                    <given-names>Ana</given-names>
                  </name>
                  <xref rid="onco13883-aff-0003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="onco13883-cr-0004" contrib-type="author">
                  <name>
                    <surname>Casado Herraez</surname>
                    <given-names>Antonio</given-names>
                  </name>
                  <xref rid="onco13883-aff-0004" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="onco13883-cr-0005" contrib-type="author">
                  <name>
                    <surname>Orlowski</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref rid="onco13883-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="onco13883-cr-0006" contrib-type="author">
                  <name>
                    <surname>Dutta</surname>
                    <given-names>Lea</given-names>
                  </name>
                  <xref rid="onco13883-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="onco13883-cr-0007" contrib-type="author">
                  <name>
                    <surname>Ren</surname>
                    <given-names>Min</given-names>
                  </name>
                  <xref rid="onco13883-aff-0006" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib id="onco13883-cr-0008" contrib-type="author">
                  <name>
                    <surname>Zale</surname>
                    <given-names>Melissa</given-names>
                  </name>
                  <xref rid="onco13883-aff-0005" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib id="onco13883-cr-0009" contrib-type="author">
                  <name>
                    <surname>O'Malley</surname>
                    <given-names>David M.</given-names>
                  </name>
                  <xref rid="onco13883-aff-0007" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="onco13883-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>Memorial Sloan Kettering Cancer Center</institution>
                <city>New York</city>
                <named-content content-type="country-part">New York</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="onco13883-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Providence Cancer Institute</institution>
                <city>Portland</city>
                <named-content content-type="country-part">Oregon</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="onco13883-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <institution>Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus</institution>
                <city>Barcelona</city>
                <country country="ES">Spain</country>
              </aff>
              <aff id="onco13883-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <institution>San Carlos University Teaching Hospital</institution>
                <city>Madrid</city>
                <country country="ES">Spain</country>
              </aff>
              <aff id="onco13883-aff-0005">
                <label>
                  <sup>5</sup>
                </label>
                <institution>Merck &amp; Co., Inc.</institution>
                <city>Kenilworth</city>
                <named-content content-type="country-part">New Jersey</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="onco13883-aff-0006">
                <label>
                  <sup>6</sup>
                </label>
                <institution>Eisai Inc.</institution>
                <city>Woodcliff Lake</city>
                <named-content content-type="country-part">New Jersey</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="onco13883-aff-0007">
                <label>
                  <sup>7</sup>
                </label>
                <institution>The Ohio State University Comprehensive Cancer Center</institution>
                <city>Columbus</city>
                <named-content content-type="country-part">Ohio</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>Correspondence: Vicky Makker, M.D., Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, New York 10065, USA. Telephone: 646‐888‐4224; e‐mail: <email>makkerv@mskcc.org</email>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>30</day>
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>9</month>
                <year>2021</year>
              </pub-date>
              <volume>26</volume>
              <issue seq="200">9</issue>
              <issue-id pub-id-type="doi">10.1002/onco.v26.9</issue-id>
              <fpage>e1599</fpage>
              <lpage>e1608</lpage>
              <history>
                <date date-type="received">
                  <day>09</day>
                  <month>4</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>22</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; AlphaMed Press 2021-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. <italic toggle="yes">The Oncologist</italic> published by Wiley Periodicals LLC on behalf of AlphaMed Press.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:ONCO-26-e1599.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="onco13883-sec-0001">
                  <title>Background</title>
                  <p>The combination of lenvatinib plus pembrolizumab has shown efficacy in treatment of advanced endometrial carcinoma (that is not microsatellite instability–high or mismatch repair deficient) following prior systemic therapy in any setting in the open‐label, single‐arm, phase Ib/II Study 111/KEYNOTE‐146. With the exception of hypothyroidism, the safety profile of the combination was comparable to that of each monotherapy. Given the medical complexity and fragility of patients with endometrial carcinoma, further characterization of adverse reactions (ARs) associated with treatment will help health care professionals to optimize treatment with lenvatinib plus pembrolizumab combination therapy.</p>
                </sec>
                <sec id="onco13883-sec-0002">
                  <title>Patients and Methods</title>
                  <p>In Study 111/KEYNOTE‐146, patients received lenvatinib at a starting dose of 20 mg orally once daily and pembrolizumab 200 mg intravenously every 3 weeks. Selected ARs (hypertension, fatigue, nausea/vomiting, diarrhea, decreased appetite/weight loss, hypothyroidism, palmar‐plantar erythrodysesthesia syndrome, musculoskeletal pain, stomatitis, and proteinuria) were chosen for detailed post hoc analyses.</p>
                </sec>
                <sec id="onco13883-sec-0003">
                  <title>Results</title>
                  <p>Median times to first onset of the selected ARs in this analysis all occurred within the first 10 weeks of treatment. Of the selected ARs, grade ≥3 severity of fatigue, hypertension, and nausea occurred in ≥5% of patients. Overall incidence of hypothyroidism was 51%, primarily of grade 2 severity (46%). Most of the ARs assessed were managed with a combination of study drug dose modifications and concomitant medications.</p>
                </sec>
                <sec id="onco13883-sec-0004">
                  <title>Conclusion</title>
                  <p>No new safety signals were identified and the toxicity profile in this study was manageable with supportive medications, dose interruptions, and/or lenvatinib dose reductions. This analysis provides AR management guidance for patients with endometrial cancer receiving lenvatinib plus pembrolizumab combination therapy.</p>
                </sec>
                <sec id="onco13883-sec-0005">
                  <title>Implications for Practice</title>
                  <p>Lenvatinib plus pembrolizumab has shown efficacy in the treatment of patients with advanced endometrial carcinoma (that is, not microsatellite instability–high or mismatch repair deficient) following at least one prior systemic therapy in any setting. Patients may experience toxicity associated with this combination, including adverse reactions of hypertension, fatigue, nausea/vomiting, diarrhea, decreased appetite/weight loss, hypothyroidism, palmar‐plantar erythrodysesthesia syndrome, musculoskeletal pain, stomatitis, and proteinuria. These adverse reactions may be managed with a combination of concomitant supportive care medications and judicious lenvatinib dose modifications. This article provides context and guidance for the recognition and management of adverse reactions in patients receiving lenvatinib plus pembrolizumab.</p>
                </sec>
              </abstract>
              <abstract abstract-type="short">
                <p>This article provides context and guidance for the recognition and management of adverse reactions in patients receiving lenvatinib plus pembrolizumab for the treatment of endometrial carcinoma.</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="onco13883-kwd-0001">Endometrial carcinoma</kwd>
                <kwd id="onco13883-kwd-0002">Lenvatinib</kwd>
                <kwd id="onco13883-kwd-0003">Pembrolizumab</kwd>
                <kwd id="onco13883-kwd-0004">Adverse reactions</kwd>
                <kwd id="onco13883-kwd-0006">Management</kwd>
              </kwd-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="4"/>
                <page-count count="10"/>
                <word-count count="7120"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>September 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.7 mode:remove_FC converted:04.09.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <fn-group id="onco13883-ntgp-0001">
                <fn id="onco13883-note-0001" fn-type="COI-statement">
                  <p>
                    <italic toggle="yes">Disclosures of potential conflicts of interest may be found at the end of this article.</italic>
                  </p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="onco13883-body-0001">
            <sec id="onco13883-sec-0006">
              <title>Introduction</title>
              <p>Endometrial cancer is the most common gynecologic cancer [<xref rid="onco13883-bib-0001" ref-type="bibr">1</xref>], with rising incidence and associated disease mortality; it is predicted to account for an estimated 66,570 new cases and 12,940 deaths in the U.S. in 2021 [<xref rid="onco13883-bib-0002" ref-type="bibr">2</xref>]. Recently, pembrolizumab, an immune checkpoint inhibitor, demonstrated efficacy in patients with solid tumors (including endometrial cancer) that are microsatellite instability–high (MSI‐H), mismatch repair deficient (dMMR), or have high tumor mutational burden [<xref rid="onco13883-bib-0003" ref-type="bibr">3</xref>, <xref rid="onco13883-bib-0004" ref-type="bibr">4</xref>]. In preclinical studies, combination of an antiprogrammed cell death 1 (PD‐1) antibody with the multikinase inhibitor lenvatinib demonstrated greater antitumor activity than either treatment alone [<xref rid="onco13883-bib-0005" ref-type="bibr">5</xref>]. Study 111/KEYNOTE‐146, a phase Ib/II trial, investigated lenvatinib plus pembrolizumab (a PD‐1 inhibitor) in selected advanced solid tumors and determined the recommended phase II dose to be lenvatinib 20 mg orally daily with pembrolizumab 200 mg intravenously (IV) every 3 weeks [<xref rid="onco13883-bib-0006" ref-type="bibr">6</xref>].</p>
              <p>Results from the endometrial carcinoma (EC) cohort of Study 111/KEYNOTE‐146 led to accelerated approval in several countries of lenvatinib plus pembrolizumab for the treatment of advanced EC that is not MSI‐H or dMMR, with disease progression following prior systemic therapy, pending results of the confirmatory phase III trial [<xref rid="onco13883-bib-0007" ref-type="bibr">7</xref>, <xref rid="onco13883-bib-0008" ref-type="bibr">8</xref>]. Specifically, in previously treated EC that was not MSI‐H or dMMR (<italic toggle="yes">n</italic> = 94), the objective response rate (ORR) was 38.3% (95% confidence interval [CI], 29–49) by independent radiologic review via RECIST version 1.1 [<xref rid="onco13883-bib-0007" ref-type="bibr">7</xref>, <xref rid="onco13883-bib-0008" ref-type="bibr">8</xref>, <xref rid="onco13883-bib-0009" ref-type="bibr">9</xref>]. Among responders, 69% of patients experienced a duration of response ≥6 months [<xref rid="onco13883-bib-0007" ref-type="bibr">7</xref>, <xref rid="onco13883-bib-0008" ref-type="bibr">8</xref>]. Median progression‐free survival for this cohort was 5.4 months (95% CI, 4.4–7.6) [<xref rid="onco13883-bib-0010" ref-type="bibr">10</xref>] and median overall survival was 16.4 months (95% CI, 13.5–25.9).</p>
              <p>The safety profile of lenvatinib plus pembrolizumab in Study 111/KEYNOTE‐146 was consistent with previous monotherapy experience of each drug [<xref rid="onco13883-bib-0007" ref-type="bibr">7</xref>, <xref rid="onco13883-bib-0008" ref-type="bibr">8</xref>], with the exception of an increased incidence of low‐grade hypothyroidism in Study 111/KEYNOTE‐146. The most common adverse reactions (ARs) in the EC study cohort among patients who were not MSI‐H or dMMR were fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, decreased weight, abdominal pain, headache, constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar‐plantar erythrodysesthesia syndrome (PPES), dyspnea, cough, and rash [<xref rid="onco13883-bib-0007" ref-type="bibr">7</xref>, <xref rid="onco13883-bib-0008" ref-type="bibr">8</xref>]. Overall, in the EC cohort, lenvatinib and/or pembrolizumab was interrupted because of a treatment‐related adverse event (AE) in 70.2% of patients, and lenvatinib was dose reduced because of a treatment‐related AE in 62.9% of patients [<xref rid="onco13883-bib-0009" ref-type="bibr">9</xref>].</p>
              <p>This post hoc analysis focuses on the characterization and management of toxicities experienced by patients with EC that was not MSI‐H or dMMR from Study 111/KEYNOTE‐146.</p>
            </sec>
            <sec id="onco13883-sec-0007">
              <title>Materials and Methods</title>
              <sec id="onco13883-sec-0008">
                <title>Patients and Study Design</title>
                <p>Eligibility criteria for Study 111/KEYNOTE‐146 have previously been published [<xref rid="onco13883-bib-0006" ref-type="bibr">6</xref>]. Selected eligibility criteria and a summary of the study endpoints are detailed in the supplemental online Methods. Lenvatinib was administered at a starting dose of 20 mg orally once daily and pembrolizumab was administered at 200 mg IV every 3 weeks.</p>
                <sec id="onco13883-sec-0009">
                  <title>
Post Hoc Subgroup Analyses
</title>
                  <p>This analysis focuses on the characterization and management of ARs in patients with EC that was not MSI‐H or dMMR who received prior systemic treatment (<italic toggle="yes">n</italic> = 94), consistent with the U.S. Food and Drug Administration (FDA)‐approved indication. The lenvatinib and pembrolizumab FDA prescribing information (PI) pools AE preferred terms into ARs, and therefore these pooled terms will be focused on herein. The most common ARs (≥20%), as pooled in the lenvatinib and pembrolizumab PIs, are shown in Table <xref rid="onco13883-tbl-0001" ref-type="table">1</xref>.</p>
                  <table-wrap position="float" id="onco13883-tbl-0001" content-type="Table">
                    <label>Table 1</label>
                    <caption>
                      <p>Adverse reactions that occurred in ≥20% of patients</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="char" char="." span="1"/>
                      <thead valign="bottom">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Most common adverse reactions (≥ 20%)</th>
                          <th align="center" valign="bottom" rowspan="1" colspan="1">Incidence (<italic toggle="yes">n</italic> = 94), %</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">65</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">65</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Musculoskeletal pain</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">65</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">64</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">52</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Hypothyroidism</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">51</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">48</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Stomatitis</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">43</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">39</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Weight loss</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">36</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Abdominal pain</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">33</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Headache</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">33</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Constipation</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">32</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Urinary tract infection</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">31</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Dysphonia</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">29</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Hemorrhagic events</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">28</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Hypomagnesemia</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">27</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">PPES</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">26</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Dyspnea</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">24</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Cough</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">21</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Rash</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">21</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot id="onco13883-ntgp-0002">
                      <fn id="onco13883-note-0003">
                        <p>Abbreviations: PPES, palmar‐plantar erythrodysesthesia syndrome.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <p>Selected ARs were chosen for further analysis based on incidence, association with study treatment, and available interventions, regardless of causality. The PIs of lenvatinib and pembrolizumab should be referred to for monitoring and management details on other important, if less common, ARs that may occur during treatment with lenvatinib plus pembrolizumab. AR criteria are discussed further in the supplemental online Methods.</p>
                </sec>
              </sec>
            </sec>
            <sec id="onco13883-sec-0010">
              <title>Results</title>
              <p>Results herein focus on selected ARs relevant to the lenvatinib plus pembrolizumab combination, from the start of enrollment on September 10, 2015, until the data cutoff date of January 10, 2019. General management recommendations and guidance for addressing ARs associated with the lenvatinib plus pembrolizumab combination, plus detailed advice specific to management of hypertension, hypothyroidism, and proteinuria, are reported in the supplemental online Results. Additional data, including dose modifications, exposure, median tumor shrinkage, last dose of lenvatinib prior to response, and tumor responses are also included in the supplemental online Results.</p>
              <sec id="onco13883-sec-0011">
                <title>Selected Adverse Reactions</title>
                <p>Selected ARs analyzed include hypertension, fatigue, nausea/vomiting, diarrhea, decreased appetite/weight loss, hypothyroidism, PPES, musculoskeletal pain, stomatitis, and proteinuria. These ARs include preferred terms that were pooled in accordance with the PIs for lenvatinib and pembrolizumab, as shown in Table <xref rid="onco13883-tbl-0002" ref-type="table">2</xref>.</p>
                <table-wrap position="float" id="onco13883-tbl-0002" content-type="Table">
                  <label>Table 2</label>
                  <caption>
                    <p>Adverse events included in each adverse reaction by preferred term</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Adverse reaction</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Preferred terms included</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Essential hypertension, hypertension, and hypertensive encephalopathy</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Asthenia, fatigue, and malaise</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea, gastroenteritis, gastrointestinal viral infection, and viral diarrhea</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Decreased appetite and early satiety</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight loss</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight decreased</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypothyroidism</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Increased blood thyroid stimulating hormone and hypothyroidism</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">PPES</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Palmar‐plantar erythrodysesthesia syndrome</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Musculoskeletal pain</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Arthralgia, arthritis, back pain, breast pain, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal stiffness, myalgia, neck pain, noncardiac chest pain, and pain in extremity</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Stomatitis</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Glossitis, mouth ulceration, oral discomfort, oral mucosal blistering, oropharyngeal pain, and stomatitis</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proteinuria</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proteinuria</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="onco13883-ntgp-0003">
                    <fn id="onco13883-note-0004">
                      <p>Abbreviations: PPES, palmar‐plantar erythrodysethesia syndrome.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Median times to first onset of the selected ARs in this analysis all occurred within the first 10 weeks of treatment (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>). AR episodes experienced per patient varied across the selected ARs, although most patients who experienced a particular AR experienced one or two episodes (Table <xref rid="onco13883-tbl-0003" ref-type="table">3</xref>). Importantly, most patients who experienced hypertension had only a single episode. Of the selected ARs, incidence of grade ≥3 fatigue, hypertension, and nausea occurred at rates ≥5%, and among each of these ARs, the duration of episodes was variable (range, 1–273 days).</p>
                <fig position="float" fig-type="Figure" id="onco13883-fig-0001">
                  <label>Figure 1</label>
                  <caption>
                    <p>Post hoc analysis of time to first onset of selected adverse reactions.</p>
                    <p><sup>a</sup>Median time to first onset in patients who experienced the adverse reaction.</p>
                    <p><sup>b</sup>All grades.</p>
                    <p><sup>c</sup>Percentages are based on the number of patients with an adverse reaction leading to a dose modification.</p>
                    <p>
                      <named-content content-type="attribution">Abbreviations: PPES, palmar‐plantar erythrodysethesia syndrome; Q1, first quartile; Q3, third quartile.</named-content>
                    </p>
                  </caption>
                  <graphic xlink:href="ONCO-26-e1599-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
                <table-wrap position="float" id="onco13883-tbl-0003" content-type="Table">
                  <label>Table 3</label>
                  <caption>
                    <p>Number of episodes per patient of selected adverse reactions of any grade</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Number of episodes</th>
                        <th align="center" valign="bottom" rowspan="1" colspan="1">Patients (<italic toggle="yes">n</italic> = 94), <italic toggle="yes">n</italic> (%)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">42 (44.68)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (11.70)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (8.51)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">39 (41.49)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18 (19.15)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (4.26)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29 (30.85)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (10.64)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6 (6.38)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20 (21.28)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5 (5.32)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (12.77)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">36 (38.30)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (12.77)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (12.77)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">39 (41.49)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (8.51)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (2.13)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Weight loss</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31 (32.98)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (3.19)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Hypothyroidism</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">45 (47.87)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (3.19)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">PPES</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (18.09)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (7.45)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Musculoskeletal pain</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31 (32.98)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9 (9.57)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21 (22.34)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Stomatitis</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (28.72)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9 (9.57)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (4.26)</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Proteinuria</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (10.64)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5 (5.32)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">≥3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (3.19)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="onco13883-ntgp-0004">
                    <fn id="onco13883-note-0005">
                      <p>Abbreviation: PPES, palmar‐plantar erythrodysethesia syndrome.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <sec id="onco13883-sec-0012">
                  <title>
Hypertension
</title>
                  <p>Hypertension is commonly graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. In Study 111/KEYNOTE‐146, hypertension was graded strictly on blood pressure (BP) without reference to the number of antihypertensive therapies. In this analysis of patients with EC that was not MSI‐H or dMMR, the median time to first onset of hypertension was 2.1 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>), and the incidence of hypertension (highest grade per patient) was as follows: overall, 65%; grade 1, 4%; grade 2, 22%; grade 3, 36%; grade 4, 2%). There were 43 episodes of grade ≥3 hypertension, with an average episode duration of 21.5 days.</p>
                  <p>Management strategies for hypertension included concomitant administration of antihypertensives and lenvatinib dose modifications; notably, the protocol for Study 111/KEYNOTE‐146 recommended medical management of hypertension (where appropriate and there was no imminent risk) before dose reduction. As such, 53.2% of patients were administered at least one medication to treat hypertension while receiving study drugs (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Among patients in this analysis who experienced at least one AR leading to a study drug dose modification, 15% received a lenvatinib dose interruption and 1% received a pembrolizumab dose interruption because of hypertension; 12% of patients received a lenvatinib dose reduction because of hypertension. Although two patients experienced grade 4 hypertension, no patients discontinued lenvatinib or pembrolizumab because of hypertension (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                  <table-wrap position="float" id="onco13883-tbl-0004" content-type="Table">
                    <label>Table 4</label>
                    <caption>
                      <p>Concomitant medications received to treat adverse reactions of interest</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col align="left" span="1"/>
                      <col align="char" char="(" span="1"/>
                      <thead valign="bottom">
                        <tr style="border-bottom:solid 1px #000000">
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Adverse reaction, medications received<xref rid="onco13883-note-0006" ref-type="table-fn"><sup>a</sup></xref> (class)</th>
                          <th align="left" valign="bottom" rowspan="1" colspan="1">Patients (<italic toggle="yes">n</italic> = 94), <italic toggle="yes">n</italic>
<xref rid="onco13883-note-0007" ref-type="table-fn"><sup>b</sup></xref> (%)</th>
                        </tr>
                      </thead>
                      <tbody valign="top">
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">50 (53.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Losartan (angiotensin II antagonist)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">25 (26.6)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Amlodipine (calcium channel blocker)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">23 (24.5)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lisinopril (ACE inhibitor)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">8 (8.5)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Metoprolol (beta blocker)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">8 (8.5)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hydralazine (active on arteriolar smooth muscle)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">6 (6.4)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Labetalol (beta blocker)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">5 (5.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Clonidine (antiadrenergic)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">5 (5.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hydrochlorothiazide (diuretic/thiazide)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Irbesartan (angiotensin II antagonist)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Enalapril (ACE inhibitor)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Fatigue</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">5 (5.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sodium chloride (IV solution)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Nausea</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">28 (29.8)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Ondansetron (antiemetic/antinauseant)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">16 (17.0)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Prochlorperazine (antiemetic/antinauseant)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">8 (8.5)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lorazepam (anxiolytic)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">8 (8.5)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Olanzapine (antipsychotic)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">6 (6.4)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Promethazine (antiemetic/antinauseant)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sodium chloride (IV solution)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">13 (13.8)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Ondansetron (antiemetic/antinauseant)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">6 (6.4)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Prochlorperazine (antiemetic/antinauseant)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Olanzapine (antipsychotic)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lorazepam (anxiolytic)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sodium chloride (IV solution)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Diarrhea</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">27 (28.7)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Loperamide (antipropulsive)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">23 (24.5)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diphenoxylate and atropine (antipropulsive)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Metronidazole (antibacterial)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sodium chloride (IV solution)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Decreased appetite</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Weight loss</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Hypothyroidism</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">45 (47.9)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Levothyroxine (thyroid preparation)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">45 (47.9)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Palmar‐plantar erythrodysesthesia syndrome</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">11 (11.7)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Paraffin (emollient/protective)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Urea (emollient/protective)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Hydroxyquinoline (antiseptic/disinfectant)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Musculoskeletal pain</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">27 (28.7)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Paracetamol (acetaminophen) (analgesic/antipyretic)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">10 (10.6)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Oxycodone (opioid)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">9 (9.6)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Fentanyl (opioid)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">5 (5.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Morphine (opioid)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Ibuprofen (nonsteroidal anti‐inflammatory)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diclofenac (topical product for joint and muscle pain)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Stomatitis</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">24 (25.5)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Dexamethasone (stomatological preparation)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">14 (14.9)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Lidocaine (stomatological preparation)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">7 (7.4)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Triamcinolone (stomatological preparation)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">4 (4.3)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Nystatin (stomatological preparation)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Mouth preparations (stomatological preparation)</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">3 (3.2)</td>
                        </tr>
                        <tr>
                          <td align="left" valign="top" rowspan="1" colspan="1">Proteinuria</td>
                          <td align="char" valign="top" rowspan="1" colspan="1">0</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot id="onco13883-ntgp-0005">
                      <fn id="onco13883-note-0006">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>Medications listed are those received by more than two patients.</p>
                      </fn>
                      <fn id="onco13883-note-0007">
                        <label>
                          <sup>b</sup>
                        </label>
                        <p>Patients may have received more than one medication to treat a specific adverse reaction.</p>
                      </fn>
                      <fn id="onco13883-note-0008">
                        <p>Abbreviations: ACE, angiotensin‐converting enzyme; IV, intravenous.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="onco13883-sec-0013">
                  <title>
Fatigue
</title>
                  <p>Fatigue is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. In this analysis, the median time to first onset of fatigue was 3.3 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>). Incidence of the highest grade of fatigue per patient was the following: overall, 65%; grade 1, 20%; grade 2, 28%; grade 3, 17%. Of the 18 episodes of grade 3 fatigue, the average duration was 32.9 days.</p>
                  <p>Overall, 5.3% of patients received at least one medication to treat fatigue while receiving study drug (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Among patients who experienced at least one AR leading to a study drug dose modification, 16% experienced a lenvatinib dose interruption, 14% experienced a pembrolizumab dose interruption, and 24% experienced a lenvatinib dose reduction because of fatigue. No patients required pembrolizumab discontinuation, and 1% of patients required lenvatinib discontinuation because of fatigue (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
                <sec id="onco13883-sec-0014">
                  <title>
Nausea and Vomiting
</title>
                  <p>Nausea is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. The median time to first onset among patients with EC that was not MSI‐H or dMMR was 4.7 weeks for patients with nausea and 5.9 weeks for patients with vomiting (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>). Most incidences of the highest grade of nausea/vomiting per patient were grade 1 or 2 (overall, 48%/39%; grade 1, 26%/28%; grade 2, 17%/12%; grade 3, 5%/0%, respectively). Of the five episodes of grade 3 nausea, the average duration was 12.0 days.</p>
                  <p>In addition to the general toxicity management strategies from the PIs and study protocol included in the supplemental online Results (management of selected adverse reactions) for lenvatinib and pembrolizumab, nausea and vomiting were also managed with concomitant medications; the study protocol required medical management of nausea and vomiting before lenvatinib dose reduction. As a result, 29.8% of patients in the study were administered at least one medication for nausea while receiving study drugs, and 13.8% of patients were given at least one medication for vomiting while receiving study drugs (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>).</p>
                  <p>Given these recommendations, among patients in this analysis who experienced at least one AR that led to a study drug dose modification, 7%/11% (nausea/vomiting) required a lenvatinib dose interruption, and 3%/4% required a pembrolizumab dose interruption; 9%/6% required a lenvatinib dose reduction because of nausea or vomiting. No patients required discontinuation of either lenvatinib or pembrolizumab because of nausea or vomiting (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
                <sec id="onco13883-sec-0015">
                  <title>
Diarrhea
</title>
                  <p>Diarrhea is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. Among patients who experienced diarrhea, the median time to first onset of diarrhea was 4.8 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>), and the majority of patients who experienced diarrhea had low‐grade events (overall, 64%; grade 1, 36%; grade 2, 23%; grade 3, 4%).</p>
                  <p>Management strategies to treat diarrhea used in this analysis included treatment with concomitant antidiarrheals in addition to the general management strategies described in the supplemental online Results (management of selected adverse reactions). In general, the lenvatinib PI suggests promptly initiating management for severe diarrhea and withholding or discontinuing of lenvatinib based on severity; the study protocol recommended optimal medical management before any study drug interruption or reduction. Within this analysis, 28.7% of patients were administered at least one medication for diarrhea while receiving study drugs (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Moreover, among patients in this analysis who experienced an AR leading to a study drug dose modification, 14% of patients required a lenvatinib dose interruption, and 6% required a pembrolizumab dose interruption; 10% of patients required a lenvatinib dose reduction because of diarrhea. No patients discontinued pembrolizumab because of diarrhea; and 1% of patients discontinued lenvatinib because of diarrhea (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
                <sec id="onco13883-sec-0016">
                  <title>
Decreased Appetite and Weight Loss
</title>
                  <p>Weight loss is characterized by a decrease in overall body weight in adults and is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. The median times to first onset of decreased appetite and weight loss were 5.1 weeks and 9.1 weeks, respectively (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>). Incidences (decreased appetite/weight loss) according to the highest grade per patient were the following: overall, 52%/36%; grade 1, 26%/9%; grade 2, 27%/24%; grade 3, 0%/3%, respectively.</p>
                  <p>In addition to dose modifications described in the supplemental online Results (management of selected adverse reactions), decreased appetite/weight loss was managed with concomitant appetite stimulants and other treatments. Among patients in this analysis, 4.3% were given at least one medication reported to treat decreased appetite and 3.2% were given medications reported to treat weight loss while receiving study drugs (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Furthermore, among patients who experienced an AR leading to study drug dose modification, 5%/3% (decreased appetite/weight loss) of patients experienced a lenvatinib dose interruption, 6%/4% of patients experienced a pembrolizumab dose interruption, and 9%/3% of patients experienced a lenvatinib dose reduction because of decreased appetite/weight loss; no patients required dose discontinuation for lenvatinib or pembrolizumab because of either AR.</p>
                </sec>
                <sec id="onco13883-sec-0017">
                  <title>
Hypothyroidism
</title>
                  <p>Hypothyroidism is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. The median time to first onset of hypothyroidism was 6.1 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>). Among patients in this analysis, most incidences of hypothyroidism were grade 2 (overall, 51%; grade 1, 4%; grade 2, 46%; grade 3, 1%). Of note, no grade 4 events of hypothyroidism were reported in this study.</p>
                  <p>Management strategies for hypothyroidism mostly included concomitant thyroid hormone replacement therapy, but some dose modifications were used when necessary. Specifically, for grade 3–4 events, thyroid hormone replacement therapy with levothyroxine or liothyronine was indicated per standard of care, and therapy with pembrolizumab was allowed to continue while thyroid replacement therapy was instituted. In this analysis, 47.9% of patients received the thyroid preparation levothyroxine during treatment (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Dose modifications for patients with hypothyroidism were minimal; 2% of patients within this analysis who experienced at least one AR that led to study drug dose modification required a lenvatinib dose interruption and 1% of patients required a pembrolizumab dose interruption because of hypothyroidism. No patients required a lenvatinib dose reduction or dose discontinuation for either study drug because of hypothyroidism (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
                <sec id="onco13883-sec-0018">
                  <title><styled-content style="fixed-case" toggle="no">Palmar‐Plantar</styled-content> Erythrodysesthesia Syndrome
</title>
                  <p>PPES is also known as hand‐foot syndrome and is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. The median time to first onset of PPES was 8.1 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>). Incidence in this study was recorded by highest grade per patient: overall, 26%; grade 1, 12%; grade 2, 11%; grade 3, 3%.</p>
                  <p>Management of PPES was done through dose modifications, as described in the supplemental online Results (Management of selected adverse reactions), and administration of concomitant medication. Overall, 11.7% of patients were administered at least one medication for PPES while receiving study drugs (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Among patients who experienced an AR that led to a study drug dose modification, 5% of patients had a lenvatinib interruption, 1% had a pembrolizumab interruption, and 13% of patients had a lenvatinib dose reduction. No patients required dose discontinuation for either study drug because of PPES (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
                <sec id="onco13883-sec-0019">
                  <title>
Musculoskeletal Pain
</title>
                  <p>Musculoskeletal pain is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. The median time to first onset of musculoskeletal pain was 2.4 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>), and the overall incidence in this analysis was 65%. The majority of patients had events that were a highest grade of grade 1 or 2 (grade 1, 31%; grade 2, 31%; grade 3, 3%).</p>
                  <p>Management strategies for musculoskeletal pain included concomitant medications and the general dose modification strategy described in the supplemental online Results (management of selected adverse reactions). Within this analysis, 28.7% of patients were given at least one medication for musculoskeletal pain while receiving study drugs (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Among patients who experienced an AR leading to a study drug dose modification, 6% of patients experienced a lenvatinib dose interruption, and 6% received a dose reduction because of musculoskeletal pain. No patients discontinued lenvatinib as a result of musculoskeletal pain. No patients discontinued pembrolizumab, and 2% of patients received a pembrolizumab interruption, because of musculoskeletal pain (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
                <sec id="onco13883-sec-0020">
                  <title>
Stomatitis
</title>
                  <p>Stomatitis is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. In this assessment of patients with EC that was not MSI‐H or dMMR, the median time to first onset of stomatitis was 5.5 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>). The overall incidence in this analysis was 43% (grade 1, 31%; grade 2, 12%).</p>
                  <p>Management strategies for stomatitis included concomitant medications and dose modifications, as outlined in the supplemental online Results (management of selected adverse reactions). Among patients in this analysis, 25.5% were given at least one medication for stomatitis while receiving study drugs (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Overall, among patients in this analysis who had an AR that led to study drug dose modification, 4% of patients experienced a lenvatinib dose interruption and 5% received a dose reduction because of stomatitis. No patients required lenvatinib or pembrolizumab discontinuation as a result of stomatitis, and 1% of patients required a pembrolizumab interruption because of stomatitis (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
                <sec id="onco13883-sec-0021">
                  <title>
Proteinuria
</title>
                  <p>Proteinuria is graded according to criteria outlined in supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">1</xref> [<xref rid="onco13883-bib-0011" ref-type="bibr">11</xref>]. The median time to first onset of proteinuria in this analysis was 3.2 weeks (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>), and the overall incidence in this analysis was 19%. Most patients had events that were a highest grade of grade 1 or 2 (grade 1, 9%; grade 2, 10%; grade 3, 1%).</p>
                  <p>Management strategies for proteinuria included regular monitoring and dose modifications. Further details on proteinuria management can be found in the supplemental online Results (management of selected adverse reactions). Within this analysis, no patients were given medication reported to treat proteinuria (Table <xref rid="onco13883-tbl-0004" ref-type="table">4</xref>). Among patients in this analysis who had an AR leading to a study drug dose modification, 4% of patients experienced a lenvatinib dose interruption, and 3% received a dose reduction because of proteinuria. No patients discontinued lenvatinib as a result of proteinuria. No patients required a pembrolizumab interruption or discontinuation because of proteinuria (Fig. <xref rid="onco13883-fig-0001" ref-type="fig">1</xref>).</p>
                </sec>
              </sec>
            </sec>
            <sec id="onco13883-sec-0022">
              <title>Discussion</title>
              <p>The safety profile of lenvatinib plus pembrolizumab in EC that was not MSI‐H or dMMR in Study 111/KEYNOTE‐146 is generally consistent with the established profiles of each agent as monotherapy [<xref rid="onco13883-bib-0008" ref-type="bibr">8</xref>, <xref rid="onco13883-bib-0012" ref-type="bibr">12</xref>, <xref rid="onco13883-bib-0013" ref-type="bibr">13</xref>].</p>
              <p>In this analysis of ARs, one important difference noted with the lenvatinib plus pembrolizumab combination therapy was that hypothyroidism occurred at a higher frequency (51%) than with either monotherapy (8% with pembrolizumab monotherapy across multiple indications; 21% of grade ≤2 in patients with unresectable hepatocellular carcinoma who received lenvatinib monotherapy [Keytruda PI, Lenvima PI]). However, the severity of hypothyroidism remained low (1% incidence of grade 3, no grade 4 or 5) and no dose reductions (lenvatinib) or discontinuations (either study drug) were needed because of hypothyroidism.</p>
              <p>Hypertension is one of the most frequently occurring ARs with lenvatinib plus pembrolizumab treatment (Table <xref rid="onco13883-tbl-0001" ref-type="table">1</xref>). Cardiovascular events, including hypertension, are widely associated with the use of tyrosine kinase inhibitors (TKIs), likely as a result of vascular endothelial growth factor (VEGF) signaling inhibition [<xref rid="onco13883-bib-0014" ref-type="bibr">14</xref>, <xref rid="onco13883-bib-0015" ref-type="bibr">15</xref>, <xref rid="onco13883-bib-0016" ref-type="bibr">16</xref>]. Although guidance from Study 111/KEYNOTE‐146 and the lenvatinib PI is informative, clinicians should ideally ensure that optimal BP control has been achieved before initiating lenvatinib therapy, as is the case for any anti‐VEGF targeting therapy. A panel composed of members of the Angiogenesis Task Force of the National Cancer Institute and experts in management of hypertension and cardiovascular toxicities in patients with cancer provided five specific recommendations for the recognition and management of hypertension associated with VEGF‐targeted therapies: (a) a risk assessment of patients to determine those potentially likely to develop hypertension, (b) addressing potential hypertension before onset of VEGF‐targeted therapy, (c) active monitoring throughout treatment but particularly within the first cycle, (d) setting goals for hypertension control, and (e) aggressive management through carefully chosen antihypertensive therapies [<xref rid="onco13883-bib-0017" ref-type="bibr">17</xref>]. It has also been suggested that patients with a high risk for hypertension, such as those on lenvatinib treatment, perform at‐home BP monitoring [<xref rid="onco13883-bib-0017" ref-type="bibr">17</xref>, <xref rid="onco13883-bib-0018" ref-type="bibr">18</xref>] with clear education regarding BP levels that warrant clinician notification. Such active BP home‐monitoring is encouraged for patients on lenvatinib therapy. Regarding the initial antihypertensive choice, prior studies have reported that VEGF inhibitor‐induced hypertension can be effectively managed with angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers and/or calcium channel blockers [<xref rid="onco13883-bib-0017" ref-type="bibr">17</xref>, <xref rid="onco13883-bib-0018" ref-type="bibr">18</xref>].</p>
              <p>Immune‐related AEs that were observed in this study including colitis, rash, hepatitis, and pneumonitis are known to occur with anti‐PD‐1 therapy, likely as a result of general immunologic enhancement [<xref rid="onco13883-bib-0015" ref-type="bibr">15</xref>, <xref rid="onco13883-bib-0019" ref-type="bibr">19</xref>].</p>
              <p>Overall, no new safety signals were identified, and the toxicity profile in this study was manageable with supportive medications, dose interruptions, and/or lenvatinib dose reductions. Among assessed patients, 16.0% experienced an AR leading to discontinuation of both study drugs, 22.3% experienced an AR leading to lenvatinib discontinuation, and 20.2% experienced an AR leading to pembrolizumab discontinuation. Of note, the onset of most of the selected ARs occurred within the first 2 months. Therefore, proactive management and close monitoring early after treatment onset may be critical to help maintain patients on the combination therapy and maximize outcomes. General management strategies for AEs associated with TKIs include concomitant supportive medications for symptom management, patient education, and dose modifications [<xref rid="onco13883-bib-0014" ref-type="bibr">14</xref>, <xref rid="onco13883-bib-0020" ref-type="bibr">20</xref>] and are similar to those used in Study 111/KEYNOTE‐146.</p>
              <p>A prompt and proactive approach in contending with emergent ARs is crucial, and several steps can be taken to optimize AR management in patients treated with lenvatinib plus pembrolizumab. Clinicians should thoroughly self‐educate regarding the common ARs of lenvatinib and pembrolizumab. Additionally, as physician assistants, nurse practitioners, and registered nurses are often the first and most frequent points of contact with patients, training the entire clinical team in recognition and management of selected ARs is important so ARs can be addressed preemptively or immediately after onset. When appropriate, teams should consider early consultant/subspecialist involvement in cases that are recalcitrant to appropriate supportive care measures and in instances of high‐grade toxicities, because a multidisciplinary management approach to optimize patient care is often necessary. ARs such as hypertension, nausea, and weight loss should be controlled before initiating therapy and preemptively addressed to the maximal extent.</p>
              <p>Certain ARs, including diarrhea and liver enzyme elevation, may be initially considered attributable to either study drug. As management strategies differ, it is important to determine the causative agent, versus an alternative etiology, that is most likely inciting the toxicity. Timing of AR onset and AR resolution with treatment interruption can be evaluated in the context of the shorter half‐life of lenvatinib. In instances in which both agents could incite an AR, if dose interruption of lenvatinib does not lead to clinical improvement, an immune‐mediated AR should be considered. In the case of diarrhea, patients should be monitored for signs and symptoms of enterocolitis (i.e., diarrhea, abdominal pain, and blood or mucus in stool with or without fever). Patients with grade ≥2 diarrhea who are suspected of colitis should undergo further evaluation and consider consultation with a gastrointestinal specialist. In the case of liver enzyme elevation, patients should be monitored for signs and symptoms of hepatitis (i.e., jaundice and malaise with or without fever), and elevated liver enzymes should be monitored frequently.</p>
              <p>Patients should be educated before treatment onset regarding the common ARs and should be well versed in the management plan of these reactions. Prophylactic prescriptions for supportive care therapies (e.g., antihypertensives, antiemetics) with clear instructions regarding initiation parameters could be considered. Teams should monitor potential ARs closely and consider weekly visits for the first two to three cycles of treatment; however, continued vigilance is important. Attention to emergent ARs should not wane over time, as late‐onset ARs (particularly immune‐mediated events) can arise.</p>
              <p>This exploratory post hoc analysis of ARs in the EC cohort of Study 111/KEYNOTE‐146 had several limitations. The study population was small. Moreover, as very few analyses were prespecified, results were descriptive in nature. Despite these limitations, this study indicated that ARs in patients treated with lenvatinib and pembrolizumab combination therapy are consistent with the known profiles of each monotherapy.</p>
              <p>Importantly, continued reductions in tumor size over time were observed among patients, despite lenvatinib dose reductions in 69.1% of patients (supplemental online Table <xref rid="onco13883-supitem-0003" ref-type="supplementary-material">2</xref>). It is notable that most of the responses (23/36; 64%) were seen at the 20‐mg dose. This suggests that clinicians should start treatment at the recommend dose of lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg IV every 3 weeks and reduce lenvatinib dosage as necessary and per label to prioritize safety and tolerability along with maximization of supportive care efforts. The data suggest that antitumor activity can continue to occur with reduced dosages of lenvatinib; however, lower starting doses could lead to inferior efficacy and not necessarily less toxicity [<xref rid="onco13883-bib-0021" ref-type="bibr">21</xref>]. This is supported by a recent study of lenvatinib in patients with differentiated thyroid cancer, which found that ORR was not noninferior in patients who started treatment at a lower starting dose compared with a higher dose [<xref rid="onco13883-bib-0022" ref-type="bibr">22</xref>]. Similar outcomes were also seen in a recent prospective study of lenvatinib plus everolimus in patients with renal cell carcinoma, in which a reduced starting dose of lenvatinib (14 mg/day) was not found to be noninferior to the approved lenvatinib starting dose of 18 mg/day [<xref rid="onco13883-bib-0023" ref-type="bibr">23</xref>], suggesting that optimal lenvatinib therapy may be achieved by starting at a higher dose and reducing as medically necessary following maximization of supportive care.</p>
              <p>A small‐scale, single‐institution, retrospective study of patients who had recurrent endometrial cancer and who were treated with lenvatinib plus pembrolizumab showed a shorter median time to treatment toxicity (defined as the time from the start of treatment until lenvatinib dose reduction or discontinuation related to toxicity, whichever occurred sooner) in patients who received the recommended 20 mg lenvatinib starting dose (<italic toggle="yes">n</italic> = 16) versus those who received reduced starting doses (<italic toggle="yes">n</italic> = 54), with no significant differences in efficacy [<xref rid="onco13883-bib-0024" ref-type="bibr">24</xref>]. Although the results of How et al. are hypothesis‐generating as to whether a lower starting dose of lenvatinib could be considered in some patients, the retrospective nature of the analysis, which included 16 patients who received lenvatinib 20 mg/day as the starting dose, should be considered. Results from prospective cohort studies published to date (across various indications) do not support alternative lenvatinib starting doses [<xref rid="onco13883-bib-0022" ref-type="bibr">22</xref>, <xref rid="onco13883-bib-0023" ref-type="bibr">23</xref>]. Additionally, patient‐reported health‐related quality‐of‐life data among patients with endometrial cancer from Study 309/KEYNOTE‐775 were recently presented [<xref rid="onco13883-bib-0025" ref-type="bibr">25</xref>] and showed that, over 12 weeks of follow‐up, similar changes in Global Health Score/quality‐of‐life outcomes were observed for patients receiving lenvatinib and pembrolizumab and those receiving treatment of physician's choice (doxorubicin or paclitaxel; −5.97; 95% CI, −8.36 to −3.58 vs. −6.98; 95% CI, −9.63 to −4.33). Therefore, despite dose holds, interruptions, and/or dose reductions that occurred in the lenvatinib and pembrolizumab arm, patient quality of life did not differ significantly from treatment of physician's choice based on the lenvatinib dose. These results further support the overall favorable benefit/risk profile of lenvatinib and pembrolizumab.</p>
              <p>Several studies in different indications have also highlighted the importance of optimally managing patient toxicities rather than discontinuing treatment. A pooled analysis of AEs in patients with radioiodine‐refractory thyroid cancer treated with lenvatinib or sorafenib concluded that early intervention and management of AEs could minimize unnecessary treatment discontinuations and improve patients' quality of life [<xref rid="onco13883-bib-0026" ref-type="bibr">26</xref>]. These results are consistent with an assessment of AEs in patients with hepatocellular carcinoma treated with lenvatinib that found prolonged median overall survival in patients who did not discontinue lenvatinib because of severe AEs [<xref rid="onco13883-bib-0027" ref-type="bibr">27</xref>].</p>
            </sec>
            <sec id="onco13883-sec-0023">
              <title>Conclusion</title>
              <p>Because patients may receive clinical benefit even after pembrolizumab treatment interruptions and lenvatinib dose interruptions and/or reductions, thorough clinical team and patient education, comprehensive patient assessments, maximization of supportive care measures, and subspecialist involvement can significantly improve patient tolerance and quality of life. Lenvatinib plus pembrolizumab combination therapy has robust, durable, and clinically meaningful activity in advanced EC that is not MSI‐H or dMMR, and as clinicians gain more experience, it is our hope that this work will provide context and guidance regarding AR management for patients receiving lenvatinib plus pembrolizumab combination therapy.</p>
            </sec>
            <sec id="onco13883-sec-0025">
              <title>Author Contributions</title>
              <p><bold>Conception/design:</bold> Vicky Makker, Matthew H. Taylor, Ana Oaknin, Antonio Casado Herraez, Robert Orlowski, Lea Dutta, Min Ren, Melissa Zale, David M. O'Malley</p>
              <p><bold>Provision of study material or patients:</bold> Vicky Makker, Matthew H. Taylor, Ana Oaknin, Antonio Casado Herraez, Robert Orlowski, Lea Dutta, Min Ren, Melissa Zale, David M. O'Malley</p>
              <p><bold>Collection and/or assembly of data:</bold> Vicky Makker, Matthew H. Taylor, Ana Oaknin, Antonio Casado Herraez, Robert Orlowski, Lea Dutta, Min Ren, Melissa Zale, David M. O'Malley</p>
              <p><bold>Data analysis and interpretation:</bold> Vicky Makker, Matthew H. Taylor, Ana Oaknin, Antonio Casado Herraez, Robert Orlowski, Lea Dutta, Min Ren, Melissa Zale, David M. O'Malley</p>
              <p><bold>Manuscript writing:</bold> Vicky Makker, Matthew H. Taylor, Ana Oaknin, Antonio Casado Herraez, Robert Orlowski, Lea Dutta, Min Ren, Melissa Zale, David M. O'Malley</p>
              <p><bold>Final approval of manuscript:</bold> Vicky Makker, Matthew H. Taylor, Ana Oaknin, Antonio Casado Herraez, Robert Orlowski, Lea Dutta, Min Ren, Melissa Zale, David M. O'Malley</p>
            </sec>
            <sec id="onco13883-sec-0026">
              <title>Disclosures</title>
              <p><bold>Vicky Makker:</bold> Merck, Eisai, Karyopharm, AstraZeneca, Clovis, Moreo, Takeda, Zymeworks, Genentech (C/A, RF—institution); <bold>Matthew H. Taylor:</bold> Bristol Myers Squibb, Eisai Inc., Novartis, Merck, Pfizer, Bayer, Sanofi/Genzyme, Regeneron, Array Biopharma, LOXO Oncology, Blueprint Medicines, Arqule, Merck (C/A), Bristol Myers Squibb, Merck Sharp &amp; Dohme, Pharmacyclics, AstraZeneca, Eisai, Incyte, EMD Serono, Novartis, Seattle Genetics, AbbVie, Genentech, Eli Lilly &amp; Co., Roche, Acerta Pharma, Genzyme Corporation, Pfizer (RF); <bold>Robert Orlowski:</bold> Merck (E, OI); <bold>Lea Dutta:</bold> Eisai Inc. (E); <bold>Min Ren:</bold> Eisai Inc. (E); <bold>Melissa Zale:</bold> Merck &amp; Co, Inc. (E); <bold>David M. O'Malley:</bold> AstraZeneca, Tesaro/GlaxoSmithKline, Immunogen, Ambry, Janssen/Johnson &amp; Johnson, AbbVie, Regeneron, Amgen, Novocure, Genentech/Roche, GOG Foundation, Iovance Biotherapeutics, Inc., Myriad Genetics, Eisai, Agenus, Tarveda, Merck, SeaGen, Novartis, Mersana, Clovis, Rubis, Elevar (C/A, SAB), AstraZeneca, Tesaro/GlaxoSmithKline, Immunogen, Janssen/Johnson &amp; Johnson, AbbVie, Regeneron, Amgen, Novocure, Genentech/Roche, VentiRx, Array Biopharma, EMD Serono, Ergomed, Ajinomoto Inc., Ludwig Cancer Research Stemcentrx, Inc., Cerulean Pharma, GOG Foundation, National Cancer Institute, Bristol Myers Squibb, Serono Inc., TRACON Pharmaceuticals, Yale University, New Mexico Cancer Care Alliance, INC Research, Inc., inVentiv Health Clinical, Iovance Biotherapeutics, Inc., PRA Intl, Eisai, Agenus, Merck, GenMab, SeaGen, Mersana, Clovis (RF—institution). The other authors indicated no financial relationships.</p>
              <p>(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material position="float" content-type="local-data">
                <p>See <ext-link xlink:href="http://www.TheOncologist.com" ext-link-type="uri">http://www.TheOncologist.com</ext-link> for supplemental material available online.</p>
              </supplementary-material>
              <supplementary-material id="onco13883-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>Appendix S1:</bold> Supplementary Information</p>
                </caption>
                <media xlink:href="ONCO-26-e1599-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="onco13883-supitem-0002" position="float" content-type="local-data">
                <caption>
                  <p><bold>Supplementary Figure 1</bold> Change in median tumor size (with interquartile range) in patients with endometrial carcinoma who received prior systemic treatment and had tumors that were not MSI‐H or dMMR (by independent review using RECIST v1.1).</p>
                  <p><bold>Supplementary Figure 2.</bold> Patient responses and lenvatinib doses over time among responders.</p>
                </caption>
                <media xlink:href="ONCO-26-e1599-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="onco13883-supitem-0003" position="float" content-type="local-data">
                <caption>
                  <p><bold>Supplementary Table 1</bold> Selected adverse event grades according to CTCAE v4.03</p>
                  <p><bold>Supplementary Table 2.</bold> Lenvatinib dose reductions and interruptions</p>
                </caption>
                <media xlink:href="ONCO-26-e1599-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="onco13883-sec-0024">
              <title>Acknowledgments</title>
              <p>Medical writing support was provided by Heather A. Mitchell, Ph.D., of Oxford PharmaGenesis Inc., Newtown, PA, and was funded by Eisai Inc., Woodcliff Lake, NJ, and also by Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ. This study was funded by Eisai Inc., Woodcliff Lake, NJ, and also by Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ. Dr. Makker is supported in part by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.</p>
            </ack>
            <ref-list id="onco13883-bibl-0001" content-type="cited-references">
              <title>References</title>
              <ref id="onco13883-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0001"><string-name><surname>Henley</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Ward</surname><given-names>EM</given-names></string-name>, <string-name><surname>Scott</surname><given-names>S</given-names></string-name> et al. <article-title>Annual report to the nation on the status of cancer, part I: National cancer statistics</article-title>. <source>Cancer</source>
<year>2020</year>;<volume>126</volume>:<fpage>2225</fpage>–<lpage>2249</lpage>.<pub-id pub-id-type="pmid">32162336</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0002"><string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <string-name><surname>Miller</surname><given-names>KD</given-names></string-name>, <string-name><surname>Fuchs</surname><given-names>HE</given-names></string-name> et al. <article-title>Cancer statistics, 2021</article-title>. <source>CA Cancer J Clin</source>
<year>2021</year>;<volume>71</volume>:<fpage>7</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">33433946</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0003"><string-name><surname>Brooks</surname><given-names>RA</given-names></string-name>, <string-name><surname>Fleming</surname><given-names>GF</given-names></string-name>, <string-name><surname>Lastra</surname><given-names>RR</given-names></string-name> et al. <article-title>Current recommendations and recent progress in endometrial cancer</article-title>. <source>CA Cancer J Clin</source>
<year>2019</year>;<volume>69</volume>:<fpage>258</fpage>–<lpage>279</lpage>.<pub-id pub-id-type="pmid">31074865</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0004"><string-name><surname>Marabelle</surname><given-names>A</given-names></string-name>, <string-name><surname>Fakih</surname><given-names>M</given-names></string-name>, <string-name><surname>Lopez</surname><given-names>J</given-names></string-name> et al. <article-title>Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open‐label, phase 2 KEYNOTE‐158 study</article-title>. <source>Lancet Oncol</source>
<year>2020</year>;<volume>21</volume>:<fpage>1353</fpage>–<lpage>1365</lpage>.<pub-id pub-id-type="pmid">32919526</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0005"><string-name><surname>Kimura</surname><given-names>T</given-names></string-name>, <string-name><surname>Kato</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ozawa</surname><given-names>Y</given-names></string-name> et al. <article-title>Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model</article-title>. <source>Cancer Sci</source>
<year>2018</year>;<volume>109</volume>:<fpage>3993</fpage>–<lpage>4002</lpage>.<pub-id pub-id-type="pmid">30447042</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0006"><string-name><surname>Taylor</surname><given-names>MH</given-names></string-name>, <string-name><surname>Lee</surname><given-names>CH</given-names></string-name>, <string-name><surname>Makker</surname><given-names>V</given-names></string-name> et al. <article-title>Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors</article-title>. <source>J Clin Oncol</source>
<year>2020</year>;<volume>38</volume>:<fpage>1154</fpage>–<lpage>1163</lpage>.<pub-id pub-id-type="pmid">31961766</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="book" id="onco13883-cit-0007"><collab collab-type="authors">Lenvima (lenvatinib)</collab>
. <source>Prescribing information</source>. <publisher-name>Eisai Inc</publisher-name>., <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="book" id="onco13883-cit-0008"><collab collab-type="authors">Keytruda (pembrolizumab)</collab>
. <source>Package insert</source>. <publisher-name>Merck Sharp &amp; Dohme Corp</publisher-name>., <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0009"><string-name><surname>Makker</surname><given-names>V</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>MH</given-names></string-name>, <string-name><surname>Aghajanian</surname><given-names>C</given-names></string-name> et al. <article-title>Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer</article-title>. <source>J Clin Oncol</source>
<year>2020</year>;<volume>38</volume>:<fpage>2981</fpage>–<lpage>2992</lpage>.<pub-id pub-id-type="pmid">32167863</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="miscellaneous" id="onco13883-cit-0010"><string-name><surname>Makker</surname><given-names>V</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>MH</given-names></string-name>, <string-name><surname>Aghajanian</surname><given-names>C</given-names></string-name> et al. <article-title>Lenvatinib and pembrolizumab in patients with advanced endometrial cancer</article-title>. Presented at: European Society for Medical Oncology; September 27–October 1, 2019; Barcelona, Spain.</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="miscellaneous" id="onco13883-cit-0011"><collab collab-type="authors">U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute</collab>
. Common Terminology Criteria for Adverse Events. Version 4.0. <year>2009</year>. Available at <ext-link xlink:href="https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf" ext-link-type="uri">https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf</ext-link>. Accessed March 31, 2021.</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0012"><string-name><surname>Schlumberger</surname><given-names>M</given-names></string-name>, <string-name><surname>Tahara</surname><given-names>M</given-names></string-name>, <string-name><surname>Wirth</surname><given-names>LJ</given-names></string-name> et al. <article-title>Lenvatinib versus placebo in radioiodine‐refractory thyroid cancer</article-title>. <source>N Engl J Med</source>
<year>2015</year>;<volume>372</volume>:<fpage>621</fpage>–<lpage>630</lpage>.<pub-id pub-id-type="pmid">25671254</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0013"><string-name><surname>Kudo</surname><given-names>M</given-names></string-name>, <string-name><surname>Finn</surname><given-names>RS</given-names></string-name>, <string-name><surname>Qin</surname><given-names>S</given-names></string-name> et al. <article-title>Lenvatinib versus sorafenib in first‐line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non‐inferiority trial</article-title>. <source>Lancet</source>
<year>2018</year>;<volume>391</volume>:<fpage>1163</fpage>–<lpage>1173</lpage>.<pub-id pub-id-type="pmid">29433850</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0014"><string-name><surname>Cabanillas</surname><given-names>ME</given-names></string-name>, <string-name><surname>Takahashi</surname><given-names>S</given-names></string-name>. <article-title>Managing the adverse events associated with lenvatinib therapy in radioiodine‐refractory differentiated thyroid cancer</article-title>. <source>Semin Oncol</source><year>2019</year>;<volume>46</volume>:<fpage>57</fpage>–<lpage>64</lpage>.<pub-id pub-id-type="pmid">30685073</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0015"><string-name><surname>Gunderson</surname><given-names>CC</given-names></string-name>, <string-name><surname>Matulonis</surname><given-names>U</given-names></string-name>, <string-name><surname>Moore</surname><given-names>KN</given-names></string-name>. <article-title>Management of the toxicities of common targeted therapeutics for gynecologic cancers</article-title>. <source>Gynecol Oncol</source><year>2018</year>;<volume>148</volume>:<fpage>591</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">29395304</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0016"><string-name><surname>Wirth</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Tahara</surname><given-names>M</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>B</given-names></string-name> et al. <article-title>Treatment‐emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT)</article-title>. <source>Cancer</source>
<year>2018</year>;<volume>124</volume>:<fpage>2365</fpage>–<lpage>2372</lpage>.<pub-id pub-id-type="pmid">29656442</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0017"><string-name><surname>Maitland</surname><given-names>ML</given-names></string-name>, <string-name><surname>Bakris</surname><given-names>GL</given-names></string-name>, <string-name><surname>Black</surname><given-names>HR</given-names></string-name> et al. <article-title>Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors</article-title>. <source>J Natl Cancer Inst</source>
<year>2010</year>;<volume>102</volume>:<fpage>596</fpage>–<lpage>604</lpage>.<pub-id pub-id-type="pmid">20351338</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0018"><string-name><surname>Nazer</surname><given-names>B</given-names></string-name>, <string-name><surname>Humphreys</surname><given-names>BD</given-names></string-name>, <string-name><surname>Moslehi</surname><given-names>J</given-names></string-name>. <article-title>Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: Focus on hypertension</article-title>. <source>Circulation</source><year>2011</year>;<volume>124</volume>:<fpage>1687</fpage>–<lpage>1691</lpage>.<pub-id pub-id-type="pmid">21986775</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0019"><string-name><surname>Postow</surname><given-names>MA</given-names></string-name>, <string-name><surname>Callahan</surname><given-names>MK</given-names></string-name>, <string-name><surname>Wolchok</surname><given-names>JD</given-names></string-name>. <article-title>Immune checkpoint blockade in cancer therapy</article-title>. <source>J Clin Oncol</source><year>2015</year>;<volume>33</volume>:<fpage>1974</fpage>–<lpage>1982</lpage>.<pub-id pub-id-type="pmid">25605845</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0020"><string-name><surname>Rimassa</surname><given-names>L</given-names></string-name>, <string-name><surname>Danesi</surname><given-names>R</given-names></string-name>, <string-name><surname>Pressiani</surname><given-names>T</given-names></string-name> et al. <article-title>Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma</article-title>. <source>Cancer Treat Rev</source>
<year>2019</year>;<volume>77</volume>:<fpage>20</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">31195212</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0021"><string-name><surname>Hayato</surname><given-names>S</given-names></string-name>, <string-name><surname>Shumaker</surname><given-names>R</given-names></string-name>, <string-name><surname>Ferry</surname><given-names>J</given-names></string-name> et al. <article-title>Exposure‐response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine‐refractory differentiated thyroid cancer</article-title>. <source>Cancer Chemother Pharmacol</source>
<year>2018</year>;<volume>82</volume>:<fpage>971</fpage>–<lpage>978</lpage>.<pub-id pub-id-type="pmid">30244318</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0022"><string-name><surname>Brose</surname><given-names>MS</given-names></string-name>, <string-name><surname>Panaseykin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Konda</surname><given-names>B</given-names></string-name> et al. <article-title>A multicenter, randomized, double‐blind, phase II study of lenvatinib (LEN) in patients (pts) with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) to evaluate the safety and efficacy of a daily oral starting dose of 18 mg vs 24 mg</article-title>. <source>Ann Oncol</source>
<year>2020</year>;<volume>31</volume>(<issue>suppl 6</issue>):<fpage>S1409a</fpage>.</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0023"><string-name><surname>Pal</surname><given-names>S</given-names></string-name>, <string-name><surname>Puente</surname><given-names>J</given-names></string-name>, <string-name><surname>Heng</surname><given-names>DYC</given-names></string-name> et al. <article-title>Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC)</article-title>. <source>Presented at: International Kidney Cancer Symposium (IKCS)</source>; November 6–7, <year>2020</year>; Virtual Meeting.</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0024"><string-name><surname>How</surname><given-names>JA</given-names></string-name>, <string-name><surname>Patel</surname><given-names>S</given-names></string-name>, <string-name><surname>Fellman</surname><given-names>B</given-names></string-name> et al. <article-title>Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer</article-title>. <source>Gynecol Oncol</source>
<year>2021</year> [epub ahead of print].</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0025"><string-name><surname>Lorusso</surname><given-names>D</given-names></string-name>, <string-name><surname>Colombo</surname><given-names>N</given-names></string-name>, <string-name><surname>Herraez</surname><given-names>AC</given-names></string-name> et al. <article-title>Health‐related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC)</article-title>. <source>J Clin Oncol</source>
<year>2021</year>;<volume>39</volume>(suppl <issue>15</issue>):<fpage>5570a</fpage>.</mixed-citation>
              </ref>
              <ref id="onco13883-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0026"><string-name><surname>Yu</surname><given-names>ST</given-names></string-name>, <string-name><surname>Ge</surname><given-names>JN</given-names></string-name>, <string-name><surname>Luo</surname><given-names>JY</given-names></string-name> et al. <article-title>Treatment‐related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: A systematic review and meta‐analysis</article-title>. <source>Cancer Manag Res</source>
<year>2019</year>;<volume>11</volume>:<fpage>1525</fpage>–<lpage>1532</lpage>.<pub-id pub-id-type="pmid">30863162</pub-id></mixed-citation>
              </ref>
              <ref id="onco13883-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="onco13883-cit-0027"><string-name><surname>Shimose</surname><given-names>S</given-names></string-name>, <string-name><surname>Iwamoto</surname><given-names>H</given-names></string-name>, <string-name><surname>Niizeki</surname><given-names>T</given-names></string-name> et al. <article-title>Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: A multicenter retrospective study</article-title>. <source>Cancers (Basel)</source>
<year>2020</year>;<volume>12</volume>:<fpage>1867</fpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
